Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

Blood

Volumn 131, Issue 1, 2018, Pages 121-130

  Hill, Joshua A ^a,b   Li, Daniel ^c   Hay, Kevin A ^b,d   Green, Margaret L ^a,b   Cherian, Sindhu ^e   Chen, Xueyan ^e   Riddell, Stanley R ^a,b   Maloney, David G ^a,b   Boeckh, Michael ^a,b   Turtle, Cameron J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Juno Therapeutics   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BACTEREMIA; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CELL DENSITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INFECTION RISK; INFECTIOUS COMPLICATION; LEUKEMIA RELAPSE; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; T LYMPHOCYTE; ACUTE LYMPHOBLASTIC LEUKEMIA; BIOLOGICAL THERAPY; COHORT ANALYSIS; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; INFECTION; METABOLISM; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION; UNITED STATES; YOUNG ADULT;

ADULT; AGED; CELL- AND TISSUE-BASED THERAPY; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; UNITED STATES; YOUNG ADULT;

EID: 85040089946     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-793760     Document Type: Article

References (28)

1. Turtle CJ, Riddell SR, Maloney DG. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. Clin Pharmacol Ther. 2016;100(3):252-258.
2. Frey NV, Porter DL. The promise of chimeric antigen receptor T-cell therapy. Oncology (Williston Park). 2016;30(10):880-888, 890.
3. Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant. 2017;23(2):235-246.
4. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD81 and CD41 CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
5. Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR-T cells of defined CD41:CD81 composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-2138.
6. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.
7. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimericantigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
9. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-528.
10. Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
11. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
12. Turtle CJ, Hay KA, Hanafi L-A, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010-3020.
13. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26): 3321-3330.
14. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]. Blood. 2014;124(2):188-195.
15. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014; 43(4):458-469.
16. De Pauw B, Walsh TJ, Donnelly JP, et al National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12): 1813-1821.
17. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(12)1487-1498.
18. Young JH, Logan BR, Wu J, et al; Blood and Marrow Transplant Clinical Trials Network Trial 0201. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22(2):359-370.
19. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiology. 1996;7(1):29-33.
20. Hay KA, Hanafi L-A, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy [published online ahead of print 18 September 2017]. Blood. doi:10.1182/blood-2017-06-793141.
21. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
22. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27): 4184-4190.
23. Hallek M, Fischer K, Fingerle-Rowson G, et al; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
24. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
25. Fishman JA, Rubin RH. Infection in organtransplant recipients. N Engl J Med. 1998; 338(24):1741-1751.
26. Tomblyn M, Chiller T, Einsele H, et al; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294]. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
27. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000; 96(6):2055-2061.
28. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-347.